veterinary biotechnology
Genflow SIRT6 Therapy Meets Endpoint in Aged-Dog Study
Genflow Biosciences Plc (LSE: GENF; OTCQB: GENFF) announced on September 8, 2026, that its SIRT6 gene-therapy study in aged dogs met its primary endpoint. The company said treated animals showed an improvement in biological age compared with untreated controls, as measured using a DNA-methylation clock. The randomized and blinded SLAB study enrolled 24 beagles over…
